EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
- 1 February 2011
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 71 (2), 241-243
- https://doi.org/10.1016/j.lungcan.2010.11.014
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMolecular Cancer, 2010
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal Of Cancer, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2008